Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
Psychedelics-focused mental healthcare company Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) (FSE: LR23) plans to take over MedBright AI Investments Inc. (CSE:MBA).
以開發精神病患者爲中心的福利公司Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) 計劃接管MedBright AI Investments Inc. (CSE: MBA)。
The proposed transaction comes as the Vancouver-based company reorganizes its operations with a near-term strategic plan toward generating positive EBITDA.
隨着這家總部位於溫哥華的公司重組運營並制定近期戰略計劃以實現創造積極的營業利潤（EBITDA），該提議的交易應運而生。
What Happened
發生了什麼
Numinus announced the execution of a letter of intent Thursday to acquire MedBright which deploys artificial intelligence and machine learning to allow medical professionals to deliver increased access to healthcare, reduce healthcare costs and improve patient outcomes, by way of a statutory plan of arrangement.
週四，Numinus宣佈執行諒解備忘錄以收購MedBright，後者採用人工智能和機器學習，讓醫療專業人員提供更加便捷的醫療服務，降低醫療成本並改善患者的治療結果，通過法定安排的計劃。
Under the deal, Numinus plans to issue 1.86 of its common shares for each MedBright AI share. It is anticipated that Numinus will issue an aggregate of approximately 204,729,372 of its shares. That will represent ownership of approximately 39% of the pro forma company on an undiluted basis, based on the current capitalization of Numinus and MedBright AI.
根據交易，Numinus計劃每股常股股票發行1.86股以換取MedBright AI的每股股票。預計Numinus將發行約2.047億4379萬372股。根據Numinus和MedBright AI目前的資本化，這將代表當前未稀釋基礎上的約39%的持股比例。
In addition, the company intends to rebrand as Numinus Intelligence upon closing of the deal. The Numinus' ticker symbol of the Toronto Stock Exchange will remain NUMI.
此外，公司打算在交易完成後改名爲Numinus Intelligence。Numinus在多倫多證券交易所的股票代碼將保持不變，爲NUMI。
See also: Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
另外，請參見：在診所重新調整和行業預期趨勢的影響下，Numinus Wellness Q2 2024營收下降。
Why It Matters
這爲以下原因非常重要
The strategic combination merges MedBright's AI-enabled clinical solution capabilities with Numinus' deep data and vast experience with drug-assisted mental health treatment to improve clinical operations and capitalize on reimbursable offerings.
這一戰略合併將MedBright的人工智能臨床解決方案能力與Numinus的深度數據和藥物輔助心理健康治療的豐富經驗相結合，以改善臨床運營並利用可報銷提供的服務。
Numinus plans to leverage its knowledge in traditional therapy, clinic management, patient care, insurance reimbursement and psychedelic-assisted therapy into a unique AI-enabled offering available to the growing number of U.S. mental health care providers.
Numinus計劃將其在傳統治療、診所管理、病人護理、保險報銷和輔助心理治療方面的專業知識與獨特的人工智能服務相結合，這種服務將供應給日益增長的美國心理健康醫療服務供應商。
As a result of the transaction, the balance sheet strengthens with cash and liquid securities more than $5 million. Moreover, the operational team continues to reduce overhead and is embarking on a revenue improvement plan for the Utah clinics.
由於本次交易，資產負債表質量得到加強，現金和流動證券超過500萬美元。此外，運營團隊繼續減少間接費用並掌握猶他州診所的收入提升計劃。
Now read: Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
現在請閱讀：猶他州醫院將很快提供用於精神健康狀況的戊二酸和MDMA療法。
What's Next
接下來怎麼做
Leaders from the MedBright AI team with experience in U.S. healthcare clinic operations and ownership plan to join the management team and Board upon the completion of the transaction.
來自MedBright AI團隊，具有美國醫療保健診所運營和所有權方面的經驗的領導人計劃在交易完成後加入管理團隊和董事會。
"We believe that harnessing our expertise and intellectual property to complement MedBright's AI technology will amplify our ability to help those in need of care while driving revenue growth and, importantly, profitability," Payton Nyquvest, CEO of Numinus said.
Numinus的首席執行官Payton Nyquvest說:“我們認爲利用我們的專業知識和知識產權來補充MedBright的人工智能技術將增強我們的幫助有需要的人獲得治療的能力，同時實現收入增長並重要的是，實現利潤。”
譯文內容由第三人軟體翻譯。